Autoimmune disorders (ADs) are encountered in 10 to 20% of patients with myelodysplastic syndromes (MDS). Available data suggest that ADs concern more often younger patients with higher risk IPSS. MDS subtypes associated with ADs are mainly MDS with single lineage dysplasia (MDS-SLD) and MDS with excess blasts (MDS-EB). Various types of ADs have been described in association with MDS, ranging from limited clinical manifestations to systemic diseases affecting multiple organs. Defined clinical entities as vasculitis, connective tissue diseases, inflammatory arthritis, and neutrophilic diseases are frequently reported; however, unclassified or isolated organ impairment can be seen. In general, ADs do not seem to confer worse survival, although certain ADs may be associated with adverse outcomes (i.e., vasculitis) or progression of MDS (Sweet syndrome). While steroids and immunosuppressive treatment (IST) remain the backbone of first-line treatment, increasing evidence suggests that MDS-specific therapy as hypomethylating agents, based on their immunomodulatory effect, may be effective in treating these complications and for sparing steroids.
Introduction
The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, with dysplasia in one or more hematopoietic cell lineages resulting in cytopenia [1] . Natural history is marked by a risk of clonal progression into acute myeloid leukemia (AML).
MDS patients can manifest overt autoimmune disorders (ADs), which pathogenesis remains unknown and the prognostic significance still controversial. ADs associated with MDS have been categorized by Saif et al. into five groups: systemic vasculitis, connective tissue disorders, isolated autoimmune phenomena, immune-mediated hematological abnormalities, and asymptomatic serological immunologic abnormalities [2] . The features of these MDS-related disorders seem to be different from those of idiopathic autoimmune diseases, especially more frequent unclassified and incomplete forms [3, 4] . In the presence of features consistent with autoimmune disorders, the physiopathological link between both disorders should be determined, as fortuitous association could be raised.
Epidemiology
According to the largest retrospective series, ADs can be associated with MDS in 10 to 20% of cases [4] [5] [6] [7] [8] (Table 1) . The prevalence and incidence may vary because of various definitions of ADs among physicians, disparities in patient's selection, and the small number of included patients. However, ADs are more frequent in patients with MDS than without MDS (32% vs 4%, p < 0.001) [10] or those with lymphoid [16] . Conversely, autoimmune diseases were associated with an increased risk of AML and MDS [17] .
Patients with MDS-associated ADs appear to be younger, with a median age of 66.7-70 years [4, 6] versus 71-73 years in the absence of ADs. The male predominance in MDS patients [1] seems to disappear in MDS-associated ADs [6, 7] .
Autoimmune disorders can precede the diagnosis of MDS or occur concomitantly to MDS in 30% of cases each. In remaining cases, ADs develop during the course of MDS with a median time of 8 months [4] , but sometimes several years after the MDS onset raising the question of possible fortuitous association [10] .
Physiopathology of MDS-related immune dysregulation disorders
Studies analyzing the physiopathological mechanisms in patients with MDS-related ADs are lacking, although various immune disorders have been described in MDS patients without associated ADs. Immune cells changes have been reported in MDS involving NK cells, lymphocytes T-CD4+ and T-CD8+, Treg, or B cells, altogether contributing to the defective immune regulation of the clonal malignant cells and progressive disease.
For instance, increased number of CD4+ Treg has been associated with unfavorable prognosis of MDS, especially in high-risk patients [18] . The bone marrow recruitment of cytotoxic T cells and the degree of dyserythropoiesis were inversely related with Treg medullar levels. Blood Treg cells levels were also shown to be an independent prognostic factor in low-risk MDS patients [19] . Treg cells upregulation could explain the impaired cytotoxic anti-tumoral response and thus contribute to malignant cells progression. Strikingly, hypomethylating agents can reverse Treg cells proliferation and immunosuppressive function in high-risk MDS [20] . Usually impaired Treg cells numbers and function have been shown in various systemic autoimmune diseases, and in MDS context could result in an ineffective control of autoreactive cells.
NK cells function have been shown recently to be also impaired in MDS, with inefficient generation of mature and functional NK cells, contributing to the disease progression through impaired immune surveillance [21] . Interestingly, hypomethylating agents can modulate in vitro the killer-cell immunoglobulin-like receptor (KIR) expression at the cell surface in high-risk MDS patients [22] , increasing NK cells anti-tumor cell suppression.
B cell differentiation and progenitors appears to be impaired in low-risk MDS [23] . Hence, more than 50% of MDS patients generate autoantibodies, mainly directed against autologous erythroblasts, reflecting increased apoptosis related to bone marrow failure, rather than the generation of pathogenic autoantibodies like in idiopathic autoimmune diseases [24] . Interestingly, in some MDS-related ADs, the B cell depletion induced by rituximab could be effective, particularly in patients with systemic vasculitis [25] .
Along with immune cells numbers and functional changes, various cytokines levels have been found to be impaired in MDS patients. Increased TNF-α level was observed in MDS patients and correlated with bone marrow cellularity, hemoglobin level, and overall survival [26] . While studies using TNF-α antagonists have been disappointing in MDS, their efficacy could be raised in some subsets of ADs, in particular MDS-related inflammatory arthritis [25] .
Altogether, these mechanisms result in the escapement of the anti-tumoral response to the malignant clonal cells, modulating the environment in a favorable layout for the malignant cells expansion. Although the precise mechanisms in MDS-related ADs remain to be determined, the reduced anti-tumoral responses could also be associated with deficient tolerance leading to the emergence of autoreactive cells and immune dysregulation disorders. Further studies are required to highlight the precise mechanisms inducing ADs in MDS patients.
Characteristics of the underlying MDS
An over-representation of MDS with multilineage dysplasia (MDS-MLD) (~25%) and MDS with excess blasts (MDS-EB) (~23%) have been shown in a recent case-control study of 788 MDS patients, whereas MDS with single lineage dysplasia (MDS-SLD) (~9%) and MDS with ring sideroblasts (MDS-RS) (~1%) seem to be less frequent in patients with ADs [4] . In comparison to MDS patients without ADs from the BGroupe Français des Myélodysplasies^(GFM), MDS-EB2 (7% vs 18%, p < 0.05) and MDS-SB (1% vs 9%, p < 0.05) were less frequently noted [4] . In another large casecontrol study, MDS subtypes were MDS-SLD (45.6%), MDS-MLD (17%), MDS-EB (28.2%), and 5q − syndrome (6%), with similar distribution in MDS patients without ADs, except for MDS-EB (21% vs 28%, respectively) [7] . The median levels of hemoglobin, platelets, and neutrophils seem to be similar in patients with and without ADs, and higher medullary blasts rates have been shown in patients with associated ADs (9% vs 5%, p < 0.05) [4] .
Autoimmune disorder characteristics
Various autoimmune diseases have been described in MDS patients. Among them, systemic diseases have been recently analyzed and classified as vasculitis, connective tissue diseases, inflammatory arthritis, neutrophilic diseases, or unclassified disorders. Facing an autoimmune disease, several arguments can raise the hypothesis of an underlying hematological malignancy (Table 2 ).
In our cohort of 123 patients, vasculitis accounted for 32% of ADs with predominantly HBV-negative polyarteritis nodosa (30%) and giant cell arteritis (23%). ANCA-negative leukocytoclasic vasculitis represents 10 to 30% of ADs [14, 27] . Behçet's-like syndrome, usually with incomplete forms and predominant digestive involvement, may represent up to 15-20% of cases, especially in MDS with trisomy 8 [4, [28] [29] [30] . MDS-related vasculitis seem to be associated with more impaired kidney function, more steroid dependency, and less complete remission than solid tumor-associated vasculitis [31] . Interestingly, some types of vasculitis have been exceptionally described in primary MDS, like ANCA-associated vasculitis, Takayasu's arteritis, or IgA vasculitis, raising even very rare association or fortuitous non-causal occurrence.
Connective tissue diseases account for 25-30% of MDSrelated ADs [4] , mostly relapsing polychondritis (~60%) and systemic lupus erythematosus (~30%). Although classical manifestations of relapsing polychondritis are also common in the paraneoplastic form (chondritis and inflammatory arthritis), skin lesions are more frequent, particularly neutrophilic dermatosis [32] [33] [34] . Other connective tissue diseases such as Sjögren's syndrome (SS) or myositis have been exceptionally reported, and no case of systemic sclerosis has been reported [6, 27] .
Inflammatory arthritis is another subset of MDS-related ADs. Among them, polymyalgia rheumatica account for1 0%, sometimes associated with giant cell arteritis [6, 35, 36] . Compared to patients without MDS, patients with inflammatory arthritis tend to be older, more often male with more involved joints [37] . Remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome) associated with MDS is characterized by more frequent steroid dependence [4, 38] . Undifferentiated arthritis represents the most frequent subset and typically present as polyarticular and symmetrical arthritis, usually without structural progression [4] .
Neutrophilic dermatosis, i.e., Sweet syndrome and pyoderma gangrenosum, is common and typical paraneoplastic diseases whose onset must warn on the occurrence of a solid tumor or hematological disease. Sweet syndrome is characterized by the presence of inflammatory papules, plaques, or nodules on the skin; systemic symptoms (fever, malaise, joint pain, and muscle pain); and neutrophilic infiltration of the skin without vasculitis. Sweet syndrome approximately accounts for~10-15% of ADs [39] and can be induced by G-CSF use or chemotherapy [40] . Neutrophilic dermatosis could be associated with 5q − syndrome and is associated with a worse prognosis of the underlying hemopathy [39] . Autoimmune cytopenias in MDS context are rather infrequent. Autoimmune hemolytic anemia (AIHA) have been reported with MDS in approximately 3% [41] , although erythrocytic autoantibodies can be founded in up to 35% of MDS patients [42] . AIHA is more likely to arise along with a lowrisk MDS, as MDS-SLD or MDS-RS [29] . Immune thrombocytopenic purpura (ITP) is also rare with few case reports [43] .
Besides these subsets, various systemic or organ-specific diseases have been reported in MDS patients, like pulmonary alveolar proteinosis. The proteinosis could be associated with particular karyotype (i.e., dicentric isochrosome of deleted 20q) and seem to be associated with a poor outcome [44] . Few cases of inflammatory bowel disease, especially Crohn's disease, are also reported with MDS [45] .
Biological immune abnormalities in MDS patients without clinical ADs
Autoantibodies (AAb) have been found in 53% of MDS patients without any clinical signs of autoimmune disorder [46] : anti-nuclear antibodies (ANA) without any specificity (20%), antiphospholipid antibodies (22%), ANCA without any specificity (9%), rheumatoid factor (12%), and anti-tissue antibodies (13%). In comparison to age-paired patients without MDS, similar frequency of autoantibodies has been found, except for anti-parietal cells AAb (p = 0.05). ANCA prevalence was found similar to the general population (3%) in another casecontrol study and seemed to be useful for the diagnosis of MDS-related vasculitis [11] . Direct antiglobulin test (DAT) positivity is reported in 5-15% of cases [8, 13] . In comparison to patients without clinical ADs, higher CRP levels and ANA titers have been shown in patients with ADs [46] , whereas when patients were treated with hypomethylating agents, they had significantly less often various autoantibodies (29% vs 53%; p = 0.07).
In most cases, autoantibodies screening remains negative, as several MDS-related diseases usually have no specific autoantibodies (PE polyarteritis nodosa, giant cell arteritis, relapsing polychondritis, or polymyalgia rheumatica).
Prognosis
The prognostic significance of MDS-associated ADs remains controversial. In part, this can be due to the heterogeneity of autoimmune diseases associated with MDS and the fact that in these studies, autoimmunity is mostly considered as one phenomenon regardless of the type of autoimmunity. Therefore, depending on types of autoimmune diseases in each cohort, the impact on survival could be different. In 123 patients with ADs and MDS, compared to 665 MDS patients, median overall survival was 72 and 75 months, respectively (p = 0.2), with similar rates of acute myeloid leukemia and deaths. Similarly, no difference in overall survival has been shown in the study by De Hollanda et al., except in the presence of cryoglobulinemic vasculitis [7] . In another prospective study of 70 patients, median overall survival was 39 months in MDSrelated AD patients (n = 13) versus 26 months (n = 57) (p = 0.76) [6] . Several small reports showed that systemic vasculitis could be associated with MDS prognosis, mostly because of the presence of high-risk MDS features [7, 47, 48] . Nevertheless, in cases of polyarteritis nodosa associated with MDS, death can be due to gastrointestinal involvement, with perforations and sepsis [48] . And in our series of vasculitis associated with MDS, an acute myeloid transformation was observed in 33% of cases in a mean time of 2.5 months after diagnosis of vasculitis. Concerning MDS cytogenetic features, karyotype distribution does not appear to be influenced by the presence of ADs. The rates of favorable cytogenetic findings (normal karyotype 5q
− , or -Y) do not differ between MDS patients with or without ADs [4, 6, 7] .
A slightly higher percentage of medullary blasts was found in patients with associated ADS (9% vs 5%) (p < 0.05) [4, 6] . Using multivariate analysis of factors associated with overall survival, IPSS scale remained the only factor associated with survival similarly to patients without ADs [4] .
Treatment of MDS-related ADs
Treatment of MDS-related ADs could be challenging because of the underlying cytopenias, the risk of infectious complications, and secondary MDS [49] . Therapeutic indication and treatment regimens must take account of the subtype of ADs, the severity of the disease, the relapse rates, and the need for specific hematological treatment for the underlying MDS (Fig. 1) .
Steroids are the most used drugs in first line and induce remission in 80 to 90% of cases [3, 4] . However, despite initial efficacy, steroid dependence or relapse occurs in 50 to 70% of cases, leading to second-line treatment, especially in case of vasculitis [31] . While response to the first line occurs in 85% of cases, only 60% of patients experiencing second-line treatment has sustained response [4] .
In steroid-dependent or refractory patients or lifethreatening disease at onset, other immunosuppressive or immunomodulating drugs including DMARDs (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide), biological targeting agents (rituximab, anti-TNF-α, tocilizumab, and anakinra) should be considered. But the hematological toxicity of methotrexate and cyclophosphamide should limit their use in these conditions.
Few reports showed interesting efficacy of biological targeting drugs, but in a French study of 29 patients, biological targeted drugs have shown poor efficacy, in comparison to non-MDS-related ADs [25] . Among them, rituximab was the most effective to induce response (65%), whereas other treatments such as anti-TNF-α antibodies or anti-interleukin antibodies (tocilizumab and anakinra) induced a response in only 1/3 of cases. Rituximab had better response in vasculitis and TNF-α antagonists in arthritis. Biological targeted drugs in MDS patients have been associated with high rates of infection (30%) and infusion-related side effects, in particular for anakinra [25] .
Inflammatory arthritis
In inflammatory arthritis, steroids are usually efficient, particularly in the initial course of the disease. Most frequent steroid dependence has been noted in MDS-related arthritis and may argue for steroid-sparing drugs combination. In undifferentiated rheumatism and RS3PE syndrome, corticosteroid therapy may be associated with sulfasalazine or hydroxychloroquine, which can even be used without steroids in mild forms. In MDS patients, DMARDs should be avoided, and salazopyrine-hydroxychloroquine combination or TNF-α antagonists, tocilizumab, or rituximab use may be considered similarly to non-MDS rheumatoid arthritis. In steroid dependent or refractory polymyalgia rheumatica, tocilizumab may be proposed [50] .
Skin involvement
In patients with neutrophilic dermatosis such as Sweet syndrome, steroids are particularly efficient inducing a prompt and complete response in almost all cases. However, steroid dependence is still frequent, requiring the use of thalidomide, dapsone, or biological targeted drugs. In isolated leukocytoclasic vasculitis, colchicine or dapsone could be used in mild forms and steroids in patients with more severe disease.
Connective tissue disease
In patients with systemic lupus erythematosus, low-dose steroids should be associated with hydroxychloroquine, whether thalidomide seems to be efficient in refractory forms. In relapsing polychondritis, steroids are highly effective to control the disease, but again steroid dependence is frequent and biological targeted drugs as anti-TNF-α antagonists may be considered.
Systemic vasculitis
In patients with systemic vasculitis in the absence of MDS, therapeutic strategy is usually tailored by the five-factor score (FFS score) [51] , in particular in polyarteritis nodosa and ANCA-positive vasculitis. Although no data are available about the value of this scale in MDS-related vasculitis, the need for combined treatment should be discussed similarly to non-MDS vasculitis. In FFS scale > 1 patient, rituximab could be associated to induce sustained remission. In giant cell arteritis, the steroid dependence and relapse seem to be similar to the idiopathic forms, and thus steroids alone should be used firstly. Tocilizumab may be added in the case of steroid dependence or frequent relapses [52] . In Behçet's-like syndrome, associated treatments, such as TNF-α antagonists, should be considered in addition with steroids because of frequent gastrointestinal complications.
Hypomethylating agents (HMA)
Azacytidine significantly improves survival in higher risk MDS [53] and is also approved for acute myeloid leukemia in patients with blasts > 30% ineligible for intensive regimens [54] .
Azacytidine efficacy in MDS-related ADs was reported in few case reports, mainly with refractory MDS-related ADs [15, [55] [56] [57] . Among 22 patients [58] , half of treated patients had int-2 or high IPSS and the remaining had low or int-1 IPSS. In low-risk patients, azacytidine was initiated for [55] , Treg lymphocytes [20] , especially in the context of post-allogeneic stem cells transplant [59] , NK cells [22] , and pro-inflammatory cytokines modulations, in particular IL-6 [60] .
To confirm these preliminary data, a non-randomized trial has been recently initiated on behalf of the French MDS network (BGroupe Francophone des Myélodysplasies^), addressing the efficacy of azacytidine in ADs associated with MDS (NCT02985190).
Bone marrow engraftment
Few studies report cases of severe or refractory autoimmune diseases in response after hematopoietic stem cell transplantation, whether in MDS-related context [61] or not [62] .
Conclusion and perspectives
Autoimmune disorders are commonly encountered in MDS patients with various subtypes and unclassified forms. The understanding of common pathways linking MDS and autoimmunity is growing with identification of deregulation in innate and adaptive immune cells, cytokine secretion, and genetic landscape underlying MDS. Although the presence of ADs does not impact neither overall survival nor progression to acute leukemia, their management is crucial to avoid steroid dependence and associated adverse events. Increasing evidence suggests that MDS-specific therapies such as azacytidine, based on their immunomodulatory effect, may be effective in treating ADs and sparing steroids concomitantly to MDS disease control. Prospective studies are ongoing to address the place of azacytidine in such situations and to help physicians in choosing the best therapeutic strategy.
